{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T06:43:29.013029+00:00","company":{"ticker":"SSKN","cik":1051514,"company_name":"STRATA Skin Sciences, Inc."},"pagination":{"limit":100,"returned":5,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"exchange_compliance_notice","fact_key":"a45a814b72030cdacf5c8e6814bf051283e6d114","cik":1051514,"ticker":"SSKN","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2025-10-14T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-02-16","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-22","notice_type":"deficiency_notice","plan_due_date":"2025-09-19","raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"August 22, 2025, Strata\nSkin Sciences, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq\nStock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement\nfor continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market\nto maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). On September\n19, 2025, the Company submitted a plan to Nasdaq to regain compliance","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-098755","anchor_url":"https://secwatch.observer/filing/0001213900-25-098755#claim-a45a814b72030cdacf5c8e6814bf051283e6d114","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1051514/000121390025098755/0001213900-25-098755-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a7f69d9370a0e5aaa1ec55bbbd500f37f9ecd471","cik":1051514,"ticker":"SSKN","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2025-10-14T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2026-02-16","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-08-22","notice_type":"noncompliance_notice","plan_due_date":"2025-09-19","raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"STRATA Skin Sciences, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"August 22, 2025, Strata\nSkin Sciences, Inc. (the “Company”) received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq\nStock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement\nfor continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market\nto maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). On September\n19, 2025, the Company submitted a plan to Nasdaq to regain compliance","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001213900-25-098755","anchor_url":"https://secwatch.observer/filing/0001213900-25-098755#claim-a7f69d9370a0e5aaa1ec55bbbd500f37f9ecd471","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1051514/000121390025098755/0001213900-25-098755-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a46d866de884f860587ae1075bc5124cb99e1474","cik":1051514,"ticker":"SSKN","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2025-08-22T23:59:59+00:00","payload":{"company_response":"evaluating courses of action, plans to submit a plan to regain compliance","compliance_status":"deficient","cure_deadline":"2025-10-03","deficiency_type":"stockholders_equity","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":"$2,500,000","notice_date":"2025-08-19","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":"Nasdaq Listing Rule 5550(b)(1)","reported_value":"below $2,500,000","rule_numbers":["5550(b)(1)"],"rules_cited_in_text":true},"claim":"STRATA Skin Sciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"August 19, 2025, Strata Skin Sciences, Inc. (the “Company”) received notice\n (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule\n 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025,\n the Company reported stockholders’ equity","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-25-032373","anchor_url":"https://secwatch.observer/filing/0001140361-25-032373#claim-a46d866de884f860587ae1075bc5124cb99e1474","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036125032373/0001140361-25-032373-index.htm"},{"fact_type":"executive_change","fact_key":"b1c68e48ad","cik":1051514,"ticker":"SSKN","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2024-11-13T23:59:59+00:00","payload":{"action":"designated","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-13","interim":false,"role":"principal financial officer and principal accounting officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"John Gillings was appointed as principal financial officer and principal accounting officer at STRATA Skin Sciences, Inc..","evidence_excerpt":"On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its principal financial officer and principal accounting officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001140361-24-046508","anchor_url":"https://secwatch.observer/filing/0001140361-24-046508#claim-b1c68e48ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124046508/0001140361-24-046508-index.htm"},{"fact_type":"earnings_release","fact_key":"c74dbdf79d40e2ce8baefdf0b4b590815eccf999","cik":1051514,"ticker":"SSKN","company_name":"STRATA Skin Sciences, Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"net loss of $0.10 per basic and diluted common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss of $3.4 million","period_text":"the first fiscal quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":"$6.8 million"},"claim":"STRATA Skin Sciences, Inc. reported the first fiscal quarter ended March 31, 2024 results: revenue $6.8 million, net income Net loss of $3.4 million, EPS net loss of $0.10 per basic and diluted common share.","evidence_excerpt":"announces its financial results for\n the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 o Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-24-026254","anchor_url":"https://secwatch.observer/filing/0001140361-24-026254#claim-c74dbdf79d40e2ce8baefdf0b4b590815eccf999","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1051514/000114036124026254/0001140361-24-026254-index.htm"}]}